241 related articles for article (PubMed ID: 34253172)
1. An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations.
Park K; Kim JS; Kim JH; Kim YC; Kim HG; Cho EK; Jin JY; Kim M; Märten A; Kang JH
BMC Cancer; 2021 Jul; 21(1):802. PubMed ID: 34253172
[TBL] [Abstract][Full Text] [Related]
2. Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
de Marinis F; Laktionov KK; Poltoratskiy A; Egorova I; Hochmair M; Passaro A; Migliorino MR; Metro G; Gottfried M; Tsoi D; Ostoros G; Rizzato S; Mukhametshina GZ; Schumacher M; Novello S; Dziadziuszko R; Tang W; Clementi L; Cseh A; Kowalski D
Lung Cancer; 2021 Feb; 152():127-134. PubMed ID: 33387727
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027.
Minegishi Y; Yamaguchi O; Sugawara S; Kuyama S; Watanabe S; Usui K; Mori M; Hataji O; Nukiwa T; Morita S; Kobayashi K; Gemma A
BMC Cancer; 2021 Mar; 21(1):208. PubMed ID: 33648453
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.
Chang JW; Huang CY; Fang YF; Chang CF; Yang CT; Kuo CS; Hsu PC; Wu CE
Thorac Cancer; 2023 Jan; 14(1):12-23. PubMed ID: 36424878
[TBL] [Abstract][Full Text] [Related]
5. Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies.
Passaro A; de Marinis F; Tu HY; Laktionov KK; Feng J; Poltoratskiy A; Zhao J; Tan EH; Gottfried M; Lee V; Kowalski D; Yang CT; Srinivasa BJ; Clementi L; Jalikop T; Huang DCL; Cseh A; Park K; Wu YL
Front Oncol; 2021; 11():709877. PubMed ID: 34307179
[TBL] [Abstract][Full Text] [Related]
6. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations.
Imai H; Kaira K; Suzuki K; Anzai M; Tsuda T; Ishizuka T; Kuwako T; Naruse I; Nemoto K; Uchino J; Morozumi N; Ishihara S; Minato K; Hisada T
Lung Cancer; 2018 Dec; 126():41-47. PubMed ID: 30527191
[TBL] [Abstract][Full Text] [Related]
8. Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group.
Agraso S; Lázaro M; Firvida XL; Santomé L; Fernández N; Azpitarte C; Leon L; Garcia C; Hudobro G; Areses MC; Campos B; Quiroga N; García J; Casal J
Cancer Treat Res Commun; 2022; 33():100646. PubMed ID: 36335799
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study.
Shi Y; Li B; Wu L; Pan Y; Pan Z; Liu Y; Fan Y; Ji Y; Fang J; Shi Q; Shi J; Gao H; Hu Y; Wang X; He Z; Ma R; Zhang Y; Jiang D; Bai Y; Zhang Y; Huang L; Zhou T; Liu H; Wang D; Wen Q; Chen G; Zang A; Wang X; Zhang X; Hu J; Yang R; Zhang G; Gu K; Wang L; Wang Q; Wei Z; Li Z; Lu H; Zhang H; Chen H; Song T
J Thorac Oncol; 2022 Oct; 17(10):1205-1215. PubMed ID: 35659581
[TBL] [Abstract][Full Text] [Related]
10. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
[TBL] [Abstract][Full Text] [Related]
11. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Park K; Tan EH; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; Yang JC; Lee KH; Lu S; Shi Y; Kim SW; Laskin J; Kim DW; Arvis CD; Kölbeck K; Laurie SA; Tsai CM; Shahidi M; Kim M; Massey D; Zazulina V; Paz-Ares L
Lancet Oncol; 2016 May; 17(5):577-89. PubMed ID: 27083334
[TBL] [Abstract][Full Text] [Related]
12. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
Lu S; Shih JY; Jang TW; Liam CK; Yu Y
Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350
[TBL] [Abstract][Full Text] [Related]
13. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
14. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
Kim MH; Choi CM; Lee SY; Park CK; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park CK; Lee SH; Jang SH; Yoon SH; Jang TW
Anticancer Res; 2022 Mar; 42(3):1615-1622. PubMed ID: 35220259
[TBL] [Abstract][Full Text] [Related]
15. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ
BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564
[TBL] [Abstract][Full Text] [Related]
16. Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment.
Yang Y; Liu Q; Cao L; Sun W; Gu X; Liu B; Xiao N; Teng F; Li X; Chen M; Yu W; Lin H; Xu G
BMC Pulm Med; 2021 May; 21(1):172. PubMed ID: 34011336
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
Yokoyama T; Yoshioka H; Fujimoto D; Demura Y; Hirano K; Kawai T; Kagami R; Washio Y; Ishida T; Kogo M; Tomii K; Okuno T; Akai M; Hirabayashi M; Nishimura T; Nakahara Y; Kim YH; Miyakoshi C; Yoshimura K; Hirai T;
Lung Cancer; 2019 Sep; 135():175-180. PubMed ID: 31446992
[TBL] [Abstract][Full Text] [Related]
18. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.
Yang JC; Schuler M; Popat S; Miura S; Heeke S; Park K; Märten A; Kim ES
J Thorac Oncol; 2020 May; 15(5):803-815. PubMed ID: 31931137
[TBL] [Abstract][Full Text] [Related]
19. Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib.
Tamura K; Nukiwa T; Gemma A; Yamamoto N; Mizushima M; Ochai K; Ikeda R; Azuma H; Nakanishi Y
Int J Clin Oncol; 2019 Aug; 24(8):917-926. PubMed ID: 30953238
[TBL] [Abstract][Full Text] [Related]
20. Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis.
Wang C; Zhao K; Hu S; Dong W; Gong Y; Xie C
Oncologist; 2023 Jun; 28(6):e397-e405. PubMed ID: 37116899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
